449 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
SNY Sanofi $43.75 $109.14B N/A
Article Searches
Emergent Begins Phase III Study on Anthrax Vaccine AV7909 http://www.zacks.com/stock/news/362304/emergent-begins-phase-iii-study-on-anthrax-vaccine-av7909?cid=CS-ZC-FT-362304 Mar 20, 2019 - Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent http://www.zacks.com/stock/news/360917/regeneron-sanofi-get-ec-nod-for-label-expansion-of-praluent?cid=CS-ZC-FT-360917 Mar 18, 2019 - Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News http://www.zacks.com/stock/news/359263/biotech-stock-roundup-regn-gets-fda-nod-for-dupixent-other-pipeline-news?cid=CS-ZC-FT-359263 Mar 13, 2019 - Key highlights of the past week are regulatory and pipeline developments.
Should Value Investors Consider Sanofi (SNY) Stock Now? http://www.zacks.com/stock/news/359203/should-value-investors-consider-sanofi-sny-stock-now?cid=CS-ZC-FT-359203 Mar 13, 2019 - Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.
Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion http://www.zacks.com/stock/news/359028/regeneron-sanofis-dupixent-gets-fda-nod-for-label-expansion?cid=CS-ZC-FT-359028 Mar 12, 2019 - The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.
Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps http://www.zacks.com/stock/news/358687/sanofis-dupixent-gets-fda-priority-status-for-nasal-polyps?cid=CS-ZC-FT-358687 Mar 11, 2019 - Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.
SNY ending 'Daily News Live' after 13-year run and will launch a new show hosted by Justine Ward http://www.nydailynews.com/sports/ny-sports-sny-dailynewslive-raissman-20190307-story.html Mar 07, 2019 -

After 13 years of unpredictable sportswriters and assorted Gasbags delivering the word and their insights on the fly every afternoon at 5 p.m., SportsNet New York is cancelling "Daily News Live" and replacing it with "The Thread" a fast-paced show covering the hottest sports news of the day.

The...

Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA http://www.zacks.com/stock/news/357971/roches-rhhby-snda-for-flu-candidate-accepted-by-the-fda?cid=CS-ZC-FT-357971 Mar 06, 2019 - The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.
Top Stock Reports for Salesforce, Booking Holdings & VMware http://www.zacks.com/research-daily/218411/top-stock-reports-for-salesforce-booking-holdings-vmware?cid=CS-ZC-FT-218411 Mar 06, 2019 - Top Stock Reports for Salesforce, Booking Holdings & VMware
3 Big Pharmas Trying to Pop the Rebate Bubble https://www.fool.com/investing/2019/03/06/3-big-pharmas-trying-to-pop-the-rebate-bubble.aspx?source=iedfolrf0000001 Mar 06, 2019 - Pharmaceutical companies are suddenly eager to lower drug prices.

Pages: 123456789...45

<<<Page 4>